Date and Time: January 6, 2026, 8AM ET Webcast: ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...
TipRanks on MSN
Bright Minds Biosciences sets January 6 webcast for BMB-101 phase 2 topline results in drug-resistant absence seizures
Bright Minds Biosciences ( ($TSE:DRUG) ) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline ...
(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...
Bright Minds Biosciences (DRUG) stock jumps as lead drug BMB-101 succeeds in a mid-stage trial against a severe neurological ...
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
The areas of the cerebral cortex that are affected in mice with absence epilepsy have been pinpointed by research that also shows that transplanting embryonic neural cells into these areas can ...
At first, the teacher described her six-year-old student as absentminded, a daydreamer. The boy was having difficulty paying attention in class. As the teacher watched the boy closely, she realized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback